This report on global antibacterial drugs market studies various drug classes used for treatment of bacterial infections along with pipeline analysis of upcoming potential drugs. Bacterial infection, irrespective of its etiology is an important concern in patients with cirrhosis since it is associated with increased morbidity and mortality. According to World Health Organization (WHO), cirrhotic patients from developed countries indicate urinary tract infections (12 - 29%) to be the most frequent cause for bacterial sepsis followed by spontaneous bacterial peritonitis (15 - 23%), respiratory tract infection (6 - 10%) and bacteremia (4-9%).
For the purpose of this study, the various drug classes studied include aminoglycosides, beta-lactams, tetracyclines, sulfonamides, quinolones, macrolides, phenicols and miscellaneous antibacterials.
The pipeline analysis for antibacterial drugs market comprises projected market sales of Phase III drugs estimated till 2029. The phase III drugs included in the pipeline analysis are solithromycin (Cempra, Inc.), VivaGel/ SPL7013 (Starpharma Holdings Limited), surotomycin (Merck & Co.), MK-3415A (Merck & Co.) and others. The report also covers qualitative information associated with the drugs under phase II and I of the clinical trials.
The geographic segmentation of the global antibacterial drugs market is performed for the regions North America, Europe, Asia Pacific and Rest of the World markets. The regions are also further sub-segmented on the basis of major countries.
According to market stakeholders, bacterial infections cause an enormous financial and physical burden of disease throughout the globe and kill millions of humans and animals. A few most common bacterial infections are pneumonia, diarrhea and meningitis, genito-urinary infections and blood infections. Recently hospital acquired diseases such as tuberculosis, pneumonia, and others are on the rise in many parts of the world. Resistance to antibiotics is now widespread among bacteria and is increasing at an alarming rate.
In base year 2021, beta-lactams accounted for the largest market share of 55.8% of the global antibacterial drugs market followed by the quinolones. In the near future these drug classes are expected to experience a decline in their market share during the forecast period 2016 to 2029 because leading brands will lose their market exclusivity, coupled with high rate of clinical trial failures, rising number of drug resistant bacterial strains and high influx of generic drugs. Thus, on the basis of the factors mentioned above, the global antibacterial drugs market is expected to witness slow growth during the forecast period 2022 to 2030. Although, the miscellaneous antibacterial drug class is expected to project noticeable growth along with rising demand for novel therapies against bacterial infections and aging population.
In base year 2021, it was observed that Asia Pacific dominated the overall market and is also projected to witness the fastest growth during the forecast period 2020 - 2030. The key factors assisting the growth of Asia Pacific antibacterial drugs market are it accounts for the largest infected population in the world with a variety of bacterial infections such as pneumonia, tuberculosis and tetanus, presence of large number of manufacturers of active pharmaceutical ingredient and generic drugs, high disposable income, rising geriatric population, and emerging healthcare infrastructure. North America, followed by Europe, is the second largest antibacterial drugs market globally in terms of revenue. North America and Europe are anticipated to witness slow growth over the forecast period due to stringent regulatory policies, abridged product lifecycle, and generic penetration.
The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
This product will be delivered within 2 business days.
For the purpose of this study, the various drug classes studied include aminoglycosides, beta-lactams, tetracyclines, sulfonamides, quinolones, macrolides, phenicols and miscellaneous antibacterials.
The pipeline analysis for antibacterial drugs market comprises projected market sales of Phase III drugs estimated till 2029. The phase III drugs included in the pipeline analysis are solithromycin (Cempra, Inc.), VivaGel/ SPL7013 (Starpharma Holdings Limited), surotomycin (Merck & Co.), MK-3415A (Merck & Co.) and others. The report also covers qualitative information associated with the drugs under phase II and I of the clinical trials.
The geographic segmentation of the global antibacterial drugs market is performed for the regions North America, Europe, Asia Pacific and Rest of the World markets. The regions are also further sub-segmented on the basis of major countries.
According to market stakeholders, bacterial infections cause an enormous financial and physical burden of disease throughout the globe and kill millions of humans and animals. A few most common bacterial infections are pneumonia, diarrhea and meningitis, genito-urinary infections and blood infections. Recently hospital acquired diseases such as tuberculosis, pneumonia, and others are on the rise in many parts of the world. Resistance to antibiotics is now widespread among bacteria and is increasing at an alarming rate.
In base year 2021, beta-lactams accounted for the largest market share of 55.8% of the global antibacterial drugs market followed by the quinolones. In the near future these drug classes are expected to experience a decline in their market share during the forecast period 2016 to 2029 because leading brands will lose their market exclusivity, coupled with high rate of clinical trial failures, rising number of drug resistant bacterial strains and high influx of generic drugs. Thus, on the basis of the factors mentioned above, the global antibacterial drugs market is expected to witness slow growth during the forecast period 2022 to 2030. Although, the miscellaneous antibacterial drug class is expected to project noticeable growth along with rising demand for novel therapies against bacterial infections and aging population.
In base year 2021, it was observed that Asia Pacific dominated the overall market and is also projected to witness the fastest growth during the forecast period 2020 - 2030. The key factors assisting the growth of Asia Pacific antibacterial drugs market are it accounts for the largest infected population in the world with a variety of bacterial infections such as pneumonia, tuberculosis and tetanus, presence of large number of manufacturers of active pharmaceutical ingredient and generic drugs, high disposable income, rising geriatric population, and emerging healthcare infrastructure. North America, followed by Europe, is the second largest antibacterial drugs market globally in terms of revenue. North America and Europe are anticipated to witness slow growth over the forecast period due to stringent regulatory policies, abridged product lifecycle, and generic penetration.
Historical & Forecast Period
This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
Research Methodology
The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Antibacterial Drugs market are as follows:- Research and development budgets of manufacturers and government spending
- Revenues of key companies in the market segment
- Number of end users and consumption volume, price and value.
- Geographical revenues generate by countries considered in the report
- Micro and macro environment factors that are currently influencing the Antibacterial Drugs market and their expected impact during the forecast period.
Market Segmentation
Drug Class
- Aminoglycosides
- Beta-Lactams
- Tetracyclines
- Sulfonamides
- Quinolones
- Macrolides
- Phenicols
Key questions answered in this report
- What are the key micro and macro environmental factors that are impacting the growth of Antibacterial Drugs market?
- What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
- Estimated forecast and market projections up to 2030.
- Which segment accounts for the fastest CAGR during the forecast period?
- Which market segment holds a larger market share and why?
- Are low and middle-income economies investing in the Antibacterial Drugs market?
- Which is the largest regional market for Antibacterial Drugs market?
- What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
- Which are the key trends driving Antibacterial Drugs market growth?
- Who are the key competitors and what are their key strategies to enhance their market presence in the Antibacterial Drugs market worldwide?
This product will be delivered within 2 business days.
Table of Contents
1. Preface
2. Executive Summary
3. Antibacterial Drugs Market: Competitive Analysis
4. Antibacterial Drugs Market: Macro Analysis & Market Dynamics
5. Antibacterial Drugs Market: By Drug Class, 2020-2030, USD (Million)
6. North America Antibacterial Drugs Market, 2020-2030, USD (Million)
7. UK and European Union Antibacterial Drugs Market, 2020-2030, USD (Million)
8. Asia Pacific Antibacterial Drugs Market, 2020-2030, USD (Million)
9. Latin America Antibacterial Drugs Market, 2020-2030, USD (Million)
10. Middle East and Africa Antibacterial Drugs Market, 2020-2030, USD (Million)
11. Company Profile
List of Figures
List of Tables
Companies Mentioned
- Pfizer Inc.
- Novartis AG
- Merck & Co.
- Astra Zeneca plc
- Johnson & Johnson Limited
- Abbott Laboratories
- li Lilly and Company
- Sanofi SA
- Bristol-Myers Squibb Company
- Bayer AG
- GlaxoSmithKline plc
